Quick Answer
Cocrystal Pharma, Inc. reported Stockholders Equity of $6.33 million for fiscal year 2025.
Cocrystal Pharma, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $6.33M | -33.5% |
| 2024 | $9.52M | -63.9% |
| 2023 | $26.38M | -33.4% |
| 2022 | $39.60M | -48.9% |
| 2021 | $77.55M | +47.7% |
| 2020 | $52.51M | +104.2% |
| 2019 | $25.71M | -61.6% |
| 2018 | $66.89M | -36.5% |
| 2017 | $105.40M | +3.0% |
| 2016 | $102.32M | -38.9% |
| 2015 | $167.59M | +2419.8% |
| 2014 | $6.65M | +175.3% |
| 2013 | -$8.83M | -76.4% |
| 2012 | -$5.01M | -80.9% |
| 2011 | -$2.77M | -370.0% |
| 2010 | -$589.2K | -160.3% |
| 2009 | -$226.4K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.67M | -39.6% | +43.8% |
| June 30, 2025 | $5.33M | -69.3% | -27.0% |
| March 31, 2025 | $7.30M | -67.7% | -23.3% |
| December 31, 2024 | $9.52M | -63.9% | -25.0% |
| September 30, 2024 | $12.70M | -58.6% | -27.0% |
| June 30, 2024 | $17.39M | -49.9% | -23.0% |
| March 31, 2024 | $22.59M | -34.9% | -14.4% |
| December 31, 2023 | $26.38M | -33.3% | -14.0% |
- Cocrystal Pharma, Inc. showed a decrease of -33.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2009–2025 period, Cocrystal Pharma, Inc.’s stockholders equity has grown by 2896.9% (from -$226.4 thousand to $6.33 million).
- The most recent figure is from Cocrystal Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: